Drug Sponsors

Oncternal Therapeutics, Tokalas merge

Wednesday, June 8, 2016

Oncternal Therapeutics and Tokalas have completed a merger to create a new world-class clinical-stage oncology company with two promising, first-in-class pipeline products. The transaction was approved by both companies’ shareholders, and results in the combination of all assets, R&D programs and operations under the name Oncternal Therapeutics.

[Read More]

Baxalta, Shire merger approved by shareholders

Wednesday, June 1, 2016

Baxalta has announced the results of a vote on the proposals identified in the definitive proxy statement/prospectus, dated April 18, 2016, at a special meeting of shareholders relating to the proposed combination with Shire. Baxalta shareholders approved the definitive merger agreement with Shire, dated as of January 11, 2016, and the merger transaction, with approximately 76.9% of shares outstanding cast in favor of the proposal, which represents approximately 98.9% of the votes cast at the meeting.

[Read More]

Arbor Pharmaceuticals to acquire XenoPort for $467M

Wednesday, June 1, 2016

Arbor Pharmaceuticals, a specialty pharmaceutical company headquartered in Atlanta, Georgia, and XenoPort, a biopharmaceutical company focused on commercializing HORIZANT, have signed a definitive agreement under which Arbor will acquire XenoPort for $7.03 per share in cash, or a total equity value of approximately $467 million. The purchase price per share represents a 60% premium to the closing price of XenoPort shares on May 20, 2016.

[Read More]

Bioclinica launches OnPoint Direct

Tuesday, May 31, 2016

Bioclinica, a specialty clinical trials technology and services provider, has introduced OnPoint Direct, a Clinical Trial Management System (CTMS) geared toward mid-market biopharma and CROs. OnPoint Direct offers a cost-friendly pricing structure that empowers organizations to adopt a full-featured clinical trial management solution without the complex configuration, capital investment or perpetual licensing models customary of other systems.

[Read More]

Bicycle Therapeutics establishes U.S. operations

Thursday, May 26, 2016

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles) platform, has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as president and chief business officer. In this newly created role, Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

[Read More]

Eli Lilly to launch 20 products through 2023

Thursday, May 26, 2016

In a presentation to the investment community, Eli Lilly stated it has the potential to launch 20 new products in the 10 years beginning in 2014 and extending through 2023. In addition, Lilly could launch an average of two new indications or line extensions for already-approved products per year during that same time period.

[Read More]

Report: 2015 broke R&D records

Monday, May 23, 2016

The Biotechnology Innovation Organization (BIO) has released a new report, “Emerging Therapeutic Company Investment and Deal Trends,” highlighting 10 years (2006-2015) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers clinical pipeline snapshots to provide context on the degree of industry partnering and the contribution of emerging companies.

[Read More]

Neuralstem plans reorganization

Friday, May 20, 2016

Neuralstem, a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company’s resources on advancing the NSI-189 neurogenic small molecule program, currently in a phase II clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cell therapy program that will expedite clinical development.

[Read More]

Novartis cuts pharmaceutical division in half

Friday, May 20, 2016

Novartis has announced changes to focus its Pharmaceuticals Division by creating two business units reporting to the CEO: Novartis Pharmaceuticals and Novartis Oncology. These business units will form the Innovative Medicines Division at Novartis. The leader of each business will join the Executive Committee of Novartis (ECN) effective July 1, 2016. Paul Hudson will be appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini will become CEO, Novartis Oncology. Both will report directly to Joseph Jimenez, CEO of Novartis. With these changes, David Epstein, currently Division Head and CEO, Novartis Pharmaceuticals, has decided to leave Novartis. 

[Read More]

Pfizer to acquire Anacor for $5.2B

Monday, May 16, 2016

Pfizer and Anacor Pharmaceuticals have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor’s flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.

[Read More]